Familial primary hypoalphalipoproteinaemia
Development and Regulatory status
Trial or other data
Dec 18: In the Phase III TANGO study, the primary endpoint (change from baseline after 24 wks vs. placebo on carotid Mean Vessel Wall Area (MVWA)) was not met .
Oct 17;According to a Cerenis Therapeutics results from PIII TANGO trial are expected at the end of Q1 2018 
Sep 15: Cerenis Therapeutics initiates the PII/III TANGO trial to evaluate the efficacy, pharmacokinetics and safety of CER 001 8 mg/kg IV infusion to prevent or reduce atherosclerosis in patients with familial primary hypoalphalipoproteinemia (CER001CLIN009; EudraCT2015-003713-23). The primary endpoint is to determine the change from baseline after 24 weeks treatment with CER 001 on carotid Mean Vessel Wall Area (MVWA) using 3T-MRI. The 48-week, double-blind, parallel, placebo-controlled, randomised trial is recruiting 30 patients in the Netherlands and will extend to Brazil, Canada, Israel, Turkey and the US .